{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:59:31Z","timestamp":1785337171842,"version":"3.55.0"},"reference-count":65,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Antidepressants such as venlafaxine and sertraline pose high risks to water ecosystems. As depressive disorders and other mental health conditions become increasingly prevalent worldwide, prescription and environmental presence of these pharmaceuticals continue to rise. This study explores the practical viability of a new framework for prescribing antidepressants\u2014integrating safety, efficacy and environmental impact. This same approach could be applied in the future for reviewing prescription of other drug classes commonly found as pollutants in water.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To assess whether environmental risks could be reduced by prioritizing less polluting active substances, shifts in prescribing practices were simulated: For sertraline, shifts were directed towards citalopram and\/or escitalopram, whereas for venlafaxine, the alternative was left unspecified due to the lack of equivalent options; a cost analysis was conducted to research economic feasibility of such an implementation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Shifting away from sertraline towards citalopram and\/or escitalopram would reduce the risk class of sertraline without increasing that of citalopram and escitalopram; the cost of such shifts would increase SSRI expenditure between 0.65% and 8.22% for Italy and reduce it between 3.53% and 12.72% in Germany. Conversely, no change in risk category is observed when the quantity of prescribed venlafaxine is reduced.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the future, clinical guidelines could be adjusted to favour first\u2010line substances with lower environmental impact but comparable efficacy, as for citalopram and escitalopram compared with sertraline. Together with strengthened implementation of non\u2010pharmacological strategies, these measures could be an active step in fighting environmental pollution and climate change, increasing global health.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70724","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:02:56Z","timestamp":1785333776000},"source":"Crossref","is-referenced-by-count":0,"title":["Environmental impact of antidepressants: Is a new prescription framework possible?"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6320-974X","authenticated-orcid":false,"given":"Matilde","family":"Bianconi","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5841-8520","authenticated-orcid":false,"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thiede","sequence":"additional","affiliation":[{"name":"Pharmaceutical Research Department Wissenschaftliches Institut der AOK (WIdO)  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sangiorgi","sequence":"additional","affiliation":[{"name":"Drug and Medical Devices Governance Area, Hospital Care Sector\u2014Personal Care, Health and Welfare Directorate Emilia\u2010Romagna Region  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Menchetti","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences University of Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Aus der BeekT WeberF\u2010A BergmannA et al.Pharmaceuticals in the environment: global occurrence and potential cooperative action under the Strategic Approach to International Chemicals Management (SAICM). Umweltbundesamt.2016."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2113947119"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.143722"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1039\/C8EM00077H"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemosphere.2019.124729"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.27"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40572\u2010014\u20100015\u2010y"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.138661"},{"key":"e_1_2_10_10_1","unstructured":"GraumnitzSJungmannD2021The database \u201cPharmaceuticals in the Environment\u201d update for the period 2017\u20132020German Environment Agency"},{"key":"e_1_2_10_11_1","unstructured":"OECD Health.OECD data explorer\u2014pharmaceuticals consumption (N06A) antidepressants 2010\u20102022.2023."},{"key":"e_1_2_10_12_1","unstructured":"GrayB vanOmmerenM LewisS et al.Mental health and COVID\u201019: early evidence of the pandemic's impact.2022."},{"key":"e_1_2_10_13_1","unstructured":"IHME U of W.GBD compare mental disorders 1990\u20132019.2015."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2020.115580"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.1040598"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2020.115092"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhazmat.2020.122245"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2020.140882"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.envpol.2019.05.099"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aquatox.2014.06.014"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbd.2019.100634"},{"key":"e_1_2_10_22_1","unstructured":"Platypuses in polluted water could ingest \u201chalf a human dose\u201d of antidepressants. ABC News.2018."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2003.10.002"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15761"},{"key":"e_1_2_10_25_1","unstructured":"GiunchiV FusaroliM LunghiC PoluzziE National report on medicines use in Italy Year 2022\u2014Chapter 7 environmental impact of medicines. Italian Medicines Agency (AIFA).2023."},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.372"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.5702"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215\u20100366(15)00224\u20102"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1192\/pb.bp.113.045054"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14475"},{"key":"e_1_2_10_31_1","unstructured":"NICE.Depression in adults: treatment and management. Natl Inst Health Care Excell.2022."},{"key":"e_1_2_10_32_1","unstructured":"Sertraline: Side Effects Uses and Dosage. In: Drugs.com. Accessed December 28 2023.https:\/\/www.drugs.com\/sertraline.html"},{"key":"e_1_2_10_33_1","unstructured":"Agenzia Italiana del Farmaco.Banca Dati Farmaci.2024."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1017\/9781108975292"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052963"},{"key":"e_1_2_10_36_1","first-page":"228","article-title":"Depressione resistente al trattamento: stato dell'arte Parte II. Trattamento","volume":"49","author":"Luchini F","year":"2014","journal-title":"Riv Psichiatr"},{"key":"e_1_2_10_37_1","unstructured":"A. CanginiFFZitoS.F. TrottaRDC2023Osservatorio nazionale sull'impiego dei medicinali. L'uso dei farmaci in Italia. Rapporto nazionale anno 2022. Roma Agenzia Italiana del Farmaco 2023. Ediguida Srl."},{"key":"e_1_2_10_38_1","unstructured":"AOK (WIdO) WI der.PharMaAnalyst.2023."},{"key":"e_1_2_10_39_1","unstructured":"LIF LA.Environmental classification of pharmaceuticals 2012 v3.0 Guidance for pharmaceutical companies.2012."},{"key":"e_1_2_10_40_1","unstructured":"Norwegian Institute of Public Health WCC for DSM.ATC\/DDD Index 2024.2024."},{"key":"e_1_2_10_41_1","unstructured":"ECHA.Guidance on information requirements and chemical safety assessment Chapter R.10: characterisation of dose [concentration]\u2010response for environment.2008."},{"key":"e_1_2_10_42_1","unstructured":"European Chemical Agency.Guidance on information requirements and chemical safety assessment.2016."},{"key":"e_1_2_10_43_1","unstructured":"ISTAT.Popolazione residente al 1\u00b0 gennaio.2024."},{"key":"e_1_2_10_44_1","unstructured":"DESTATIS.Bev\u00f6lkerung nach nationalit\u00e4t und geschlecht (quartalszahlen).2024."},{"key":"e_1_2_10_45_1","unstructured":"GiunchiV.PNEC repository.2023.10.17605\/OSF.IO\/XTG8Z."},{"key":"e_1_2_10_46_1","unstructured":"EMA.Guideline on the environmental risk assessment of medicinal products for human use.2018."},{"key":"e_1_2_10_47_1","unstructured":"List of pharmaceuticals. Accessed March 24 2025.https:\/\/www.aifa.gov.it\/liste-dei-farmaci"},{"key":"e_1_2_10_48_1","unstructured":"AIFA\u2014ricerca farmaco. Accessed March 3 2025.https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/risultati?query=escitalopram&spellingCorrection=true"},{"key":"e_1_2_10_49_1","unstructured":"ratiopharm.Escitalopram\u2010ratiopharm filmtabletten\u2014FACHINFORMATION.2024."},{"key":"e_1_2_10_50_1","unstructured":"ratiopharm.Citalopram\u2010ratiopharm filmtabletten\u2014FACHINFORMATION.2024."},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0355"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)32802\u20107"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1177\/07067437241245384"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2345"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.0777"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.1035"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2016.1180248"},{"key":"e_1_2_10_58_1","unstructured":"NVL.2022NVL unipolare depressionNatl Versorg"},{"key":"e_1_2_10_59_1","unstructured":"Environmental risk assessment of medicinal products for human use\u2014scientific guideline. European Medicines Agency (EMA).2024."},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/etc.3259"},{"key":"e_1_2_10_61_1","unstructured":"Region Stockholm Janusinfo\u2014environment and pharmaceuticals. Accessed December 5 2023.https:\/\/janusinfo.se\/beslutsstod\/lakemedelochmiljo\/pharmaceuticalsandenvironment.4.7b57ecc216251fae47487d9a.html"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21120"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20102667(22)00057\u20103"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/978\u20103\u2010030\u201082587\u20104"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2023.105443"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21057"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70724","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70724","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:03:00Z","timestamp":1785333780000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":65,"alternative-id":["10.1002\/bcp.70724"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70724","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"bcp.70724"}}